Clinical Trial

A Study to Evaluate the SYH2053 Injection in Patients With Heterozygous Familial Hypercholesterolemia (HeFH)

Recruiting Phase 3
View on ClinicalTrials.gov →
Summary
Heterozygous Familial Hypercholesterolemia (HeFH) is an autosomal dominant disorder characterized by markedly elevated low-density lipoprotein cholesterol (LDL-C) and increased risk of atherosclerotic cardiovascular disease (ASCVD). This trial aims to evaluate the SYH2053 Injection in patients with HeFH.
Protocol Amendment History 1 change
critical Recruitment opened 2026-07-09
Trial Details
NCT Number NCT07465263
Lead Sponsor CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd.
Conditions Heterozygous Familial Hypercholesterolemia (HeFH)
Enrollment 135 participants
Start Date 2026-03-31
Primary Completion 2028-02-28 (estimated)
Study Completion 2028-05-31 (estimated)
Updated on ClinicalTrials.gov 2026-07-08